Pharma sector: Look beyond the tariff reprieve for generics. 6 mid-cap pharma stocks with an upside potential of more than 23%

With US President Trump, nothing can be ruled out. But, for now at least, Indian pharma companies can breathe a little easier. The 100% tariff shock on pharmaceutical imports into the US from October 1 is limited to patented and branded drugs. Generic drugs have been kept out of it. And the bulk of Indian exports to the world comprise generics. So the threat hanging over pharma companies is gone for now. But, as we said, nothing can be ruled out where Trump is concerned.